Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | PKLR | P30613 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28139974 | 0.86 | PKLR (0.37) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL22014300 | 0.83 | CYP2D6 (0.36) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL12950188 | 0.83 | OPRM1 (0.53) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL20148097 | 0.81 | OPRM1 (0.51) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL378748 | 0.79 | OPRM1 (0.47) | OPRM1SLC6A4PKLRLMNAMEN1 | |
| SCHEMBL10567693 | 0.79 | OPRM1 (0.49) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL398929 | 0.79 | PKLR (0.42) | PKLRMEN1KMT2A | |
| SCHEMBL19325498 | 0.77 | OPRM1 (0.48) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| Hydrochloric Acid SCHEMBL3320046 | 0.77 | OPRM1 (0.46) | OPRM1SLC6A4OPRD1OPRK1PKLR | |
| SCHEMBL19325450 | 0.76 | OPRM1 (0.47) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324250-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2408745-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-10-07 | — | — | US | disclosed |
| WO-2010106081-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HTR3A, OPRL1, OPRK1 | OPRM1 24/4885SLC22A1 2537/4885SLC6A4 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.